Board meeting on Oct 30 to consider Q2 and H1 FY26 financial results

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹32.59

prior close

₹34.21

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.6%+7.6% vs market

Biotechnology peers, median of 5sector+0.0%+5.0% vs sector

On the reaction day the stock moved 7.6 pts more than Nifty Microcap 250 and 5.0 pts more than its Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0-2.6+7.6+0.0+5.0

Next day

+10.2-3.6+13.8-2.1+12.4

+15.7-5.8+21.6-2.4+18.1

+21.5-5.5+27.0-3.4+24.8

+27.5-3.8+31.4+0.0+27.5

+33.9pendingpending+0.0+33.9

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Biotechnology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Genomic Valley Biotech has scheduled a board meeting on Friday, October 30, 2026 to consider and approve unaudited standalone financial results for the quarter and half year ended September 30, 2026. The trading window for directors, KMPs, promoters and designated persons is closed from October 1, 2026 until 48 hours after results are announced. This is a standard advance intimation under SEBI LODR Regulation 29. No actual numbers have been disclosed yet.

Likely market impact

No immediate price impact. Watch for Q2 and H1 FY26 results on or after October 30, 2026. Stock may move once numbers are out.